免疫治疗应用后晚期非小细胞肺癌年龄与生存趋势的关联
这项队列研究纳入美国约280家社区肿瘤诊所的53,719例晚期非小细胞肺癌患者,评估免疫检查点抑制剂(ICI)使用和生存随年龄的变化趋势。ICI使用率从2015年的4.7%升至2019年的45.6%,各年龄组使用率相似;2年生存概率在<55岁患者从37.7%升至50.3%,在≥75岁患者从30.6%升至36.2%,但最年长患者生存获益相对有限。
要点
- ICI使用率从2015年4.7%升至2019年45.6%(P<.001),<55岁与≥75岁患者2019年使用率相似(45.2% vs 43.8%,P=.59)。
- 2011至2018年,<55岁患者2年生存概率从37.7%升至50.3%,≥75岁患者从30.6%升至36.2%(P<.001)。
- 中位生存<55岁患者从11.5个月延长至16.0个月,≥75岁患者从9.1个月延长至10.2个月。
核心结论
- 在美国食品药品监督管理局批准ICI用于NSCLC后,所有年龄组患者ICI使用迅速普及,但相应的生存获益有限,尤其在最年长患者中。
研究设计与样本
- 这项队列研究在约280家以社区为基础的美国癌症诊所开展,纳入2011年1月1日至2019年12月31日诊断为IIIB、IIIC或IV期NSCLC的18岁及以上患者,随访至2020年12月31日,数据分析时间为2021年4月1日至2022年10月19日。
主要发现
- 研究样本共53,719例患者(平均[SD]年龄68.5[9.3]岁;男性28,374例[52.8%]),其中大多数为白人(36,316例[67.6%])。
- 接受癌症导向治疗的患者比例从2011年的69.0%升至2019年的77.2%。
- ICI使用率从2015年的4.7%升至2019年的45.6%(P<.001);2019年<55岁患者与≥75岁患者使用率相似(45.2% vs 43.8%,P=.59)。
- 2011年至2018年,预测2年生存概率在<55岁患者从37.7%升至50.3%,在≥75岁患者从30.6%升至36.2%(P<.001)。
- 中位生存期在<55岁患者从11.5个月延长至16.0个月,在≥75岁患者从2011年的9.1个月延长至2019年的10.2个月。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
IMPORTANCE: The introduction of immune checkpoint inhibitors (ICIs) has transformed the care of advanced non-small cell lung cancer (NSCLC). Although clinical trials suggest substantial survival benefits, it is unclear how outcomes have changed in clinical practice. OBJECTIVE: To assess temporal trends in ICI use and survival among patients with advanced NSCLC across age strata. DESIGN, SETTING, AND PARTICIPANTS: This cohort study was performed in approximately 280 predominantly community-based US cancer clinics and included patients aged 18 years or older who had stage IIIB, IIIC, or IV NSCLC diagnosed between January 1, 2011, and December 31, 2019, with follow-up through December 31, 2020. Data were analyzed April 1, 2021, to October 19, 2022. MAIN OUTCOMES AND MEASURES: Median overall survival and 2-year survival probability. The predicted probability of 2-year survival was calculated using a mixed-effects logit model adjusting for demographic and clinical characteristics. RESULTS: The study sample included 53 719 patients (mean [SD] age, 68.5 [9.3] years; 28 374 men [52.8%]), the majority of whom were White individuals (36 316 [67.6%]). The overall receipt of cancer-directed therapy increased from 69.0% in 2011 to 77.2% in 2019. After the first US Food and Drug Administration approval of an ICI for NSCLC, the use of ICIs increased from 4.7% in 2015 to 45.6% in 2019 (P < .001). Use of ICIs in 2019 was similar between the youngest and oldest patients (aged <55 years, 45.2% vs aged ≥75 years, 43.8%; P = .59). From 2011 to 2018, the predicted probability of 2-year survival increased from 37.7% to 50.3% among patients younger than 55 years and from 30.6% to 36.2% in patients 75 years or older (P < .001). Similarly, median survival in patients younger than 55 years increased from 11.5 months to 16.0 months during the study period, while survival among patients 75 years or older increased from 9.1 months in 2011 to 10.2 months in 2019. CONCLUSIONS AND RELEVANCE: This cohort study found that, among patients with advanced NSCLC, the uptake of ICIs after US Food and Drug Administration approval was rapid across all age groups. However, corresponding survival gains were modest, particularly in the oldest patients.
引用
- Voruganti T, Soulos PR, Mamtani R, et al. Association Between Age and Survival Trends in Advanced Non-Small Cell Lung Cancer After Adoption of Immunotherapy. JAMA Oncol. 2023. PMID: 36701150. doi:10.1001/jamaoncol.2022.6901
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。